• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Refining Tolvaptan Dosing in ADPKD: The Role of Urinary Biomarkers in Enhancing Outcomes.

作者信息

De Rosa Liliana Italia, Catania Martina, Kola Kristiana, Paolisi Michele, Bianca Pierpaolo, Manunta Paolo, Vezzoli Giuseppe, Sciarrone Alibrandi Maria Teresa

机构信息

Vita Salute San Raffaele University, Milan, Italy.

O.U. Nephrology and Dialysis, San Raffaele Scientific Institute, Milan, Italy.

出版信息

Kidney Int Rep. 2025 May 27;10(8):2879. doi: 10.1016/j.ekir.2025.03.059. eCollection 2025 Aug.

DOI:10.1016/j.ekir.2025.03.059
PMID:40814604
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12348245/
Abstract
摘要

相似文献

1
Refining Tolvaptan Dosing in ADPKD: The Role of Urinary Biomarkers in Enhancing Outcomes.优化常染色体显性多囊肾病中托伐普坦的给药方案：尿生物标志物在改善治疗结果中的作用
Kidney Int Rep. 2025 May 27;10(8):2879. doi: 10.1016/j.ekir.2025.03.059. eCollection 2025 Aug.
2
Response to the Letter to the Editor Entitled "Refining Tolvaptan Dosing in ADPKD: The Role of Urinary Biomarkers in Enhancing Outcomes".对题为《优化常染色体显性多囊肾病中托伐普坦的给药剂量：尿生物标志物在改善预后中的作用》的致编辑信的回复
Kidney Int Rep. 2025 May 28;10(8):2880. doi: 10.1016/j.ekir.2025.05.040. eCollection 2025 Aug.
3
The effect of tolvaptan on renal progression and systemic inflammation in ADPKD.托伐普坦对常染色体显性多囊肾病肾脏进展及全身炎症的影响。
Sci Rep. 2025 Sep 1;15(1):32228. doi: 10.1038/s41598-025-15681-7.
4
Visceral Adiposity and Progression of ADPKD: A Cohort Study of Patients From the TEMPO 3:4 Trial.内脏脂肪与常染色体显性多囊肾病的进展：来自TEMPO 3:4试验患者的队列研究
Am J Kidney Dis. 2024 Sep;84(3):275-285.e1. doi: 10.1053/j.ajkd.2024.02.014. Epub 2024 Apr 10.
5
Prostaglandin E2, Osmoregulation, and Disease Progression in Autosomal Dominant Polycystic Kidney Disease.前列腺素 E2、渗透压调节和常染色体显性多囊肾病的疾病进展。
Clin J Am Soc Nephrol. 2023 Nov 1;18(11):1426-1434. doi: 10.2215/CJN.0000000000000269. Epub 2023 Aug 14.
6
The safety and efficacy of tolvaptan in the treatment of patients with autosomal dominant polycystic kidney disease: A systematic review and meta-analysis.托伐普坦治疗常染色体显性遗传性多囊肾病患者的安全性和有效性：一项系统评价和荟萃分析。
Nefrologia (Engl Ed). 2023 Nov-Dec;43(6):731-741. doi: 10.1016/j.nefroe.2023.04.002. Epub 2023 May 5.
7
Effects of Octreotide-Long-Acting Release Added-on Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease: Pilot, Randomized, Placebo-Controlled, Cross-Over Trial.奥曲肽长效释放制剂联合托伐普坦治疗常染色体显性遗传多囊肾病的效果：一项先导、随机、安慰剂对照、交叉试验。
Clin J Am Soc Nephrol. 2023 Feb 1;18(2):223-233. doi: 10.2215/CJN.0000000000000049.
8
Interventions for preventing the progression of autosomal dominant polycystic kidney disease.用于预防常染色体显性遗传性多囊肾病进展的干预措施。
Cochrane Database Syst Rev. 2024 Oct 2;10(10):CD010294. doi: 10.1002/14651858.CD010294.pub3.
9
Kidney Function Trajectories with Tolvaptan in ADPKD Patients with CKD-G5.托伐普坦治疗慢性肾脏病5期常染色体显性多囊肾病患者的肾功能轨迹
Kidney Int Rep. 2025 Mar 17;10(6):1864-1873. doi: 10.1016/j.ekir.2025.03.020. eCollection 2025 Jun.
10
The long-term effect of tolvaptan treatment on kidney function and volume in patients with ADPKD.托伐普坦治疗对常染色体显性多囊肾病患者肾功能及肾脏体积的长期影响。
Nephrol Dial Transplant. 2025 Aug 29;40(9):1764-1774. doi: 10.1093/ndt/gfaf048.

本文引用的文献

1
Urine Osmolality Is a Potential Marker of Longer-Term Efficacy of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis.尿渗透压是托伐普坦治疗常染色体显性遗传多囊肾病长期疗效的潜在标志物：一项事后分析。
Kidney360. 2024 Jul 1;5(7):996-1001. doi: 10.34067/KID.0000000000000485. Epub 2024 Jun 10.
2
Prospective Study on Individualized Dose Adjustment of Tolvaptan Based on Urinary Osmolality in Patients With ADPKD.基于尿渗透压的托伐普坦个体化剂量调整在常染色体显性多囊肾病患者中的前瞻性研究
Kidney Int Rep. 2024 Jan 12;9(4):1031-1039. doi: 10.1016/j.ekir.2024.01.020. eCollection 2024 Apr.
3
What is the Appropriate Dose of Tolvaptan in ADPKD?托伐普坦治疗常染色体显性多囊肾病的合适剂量是多少？
Kidney Int Rep. 2024 Feb 1;9(4):737-739. doi: 10.1016/j.ekir.2024.01.049. eCollection 2024 Apr.
4
[Psychological Assessment of a sample of women with ADPKD: quality of life, body image, anxiety and depression].
G Ital Nefrol. 2019 Apr;36(2).
5
Tolvaptan: A Review in Autosomal Dominant Polycystic Kidney Disease.托伐普坦：常染色体显性遗传多囊肾病治疗药物的研究进展。
Drugs. 2019 Feb;79(3):303-313. doi: 10.1007/s40265-019-1056-1.